Mallinckrodt to sell industrial unit

Article

Mallinckrodt executives are looking to reposition the firm to focus solely on its healthcare business, according to an announcement made in late January by the St. Louis-based company. The firm is exploring the divestiture of its industrial specialty

Mallinckrodt executives are looking to reposition the firm to focus solely on its healthcare business, according to an announcement made in late January by the St. Louis-based company. The firm is exploring the divestiture of its industrial specialty chemicals business, and is also actively looking to sell a Nellcor Puritan Bennett business that manufactures oxygen equipment, passenger service units, and video systems for the aerospace industry. Mallinckrodt bought Nellcor last year (SCAN 10/1/97).

In other news, for its 1998 fiscal second quarter (end-December), Mallinckrodt had net sales of $656.2 million, up 45% from the $453.1 million reported a year ago, thanks to the Nellcor acquisition. Earnings from continuing operations before charges related to the Nellcor buy were $24.4 million. The company had posted earnings from continuing operations of $39.1 million in its 1997 fiscal second quarter.

After acquisition- and divestiture-related items were included, Mallinckrodt realized a net loss of $4.7 million. Net income for the same period last year was $43.5 million. Operating earnings in the firm's healthcare segment dipped 5% from the same period last year, a decline attributed primarily to pricing drops in imaging agents.

Finally, Raymond Larkin has resigned from his position as executive vice president of Mallinckrodt and president and CEO of Nellcor Puritan Bennett to pursue other interests. Larkin's last day with Mallinckrodt will be March 31.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.